Optimizing therapy of seizures in children and adolescents with developmental disabilities

Neurology

Volumn 67, Issue 12 SUPPL. 4, 2006, Pages

  Smith, Michael C ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ERYTHROMYCIN; ETIRACETAM; FELBAMATE; LAMOTRIGINE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE;

ATAXIA; BONE DISEASE; CHILD; CONNECTIVE TISSUE DISEASE; DEVELOPMENTAL DISORDER; DIZZINESS; DRUG WITHDRAWAL; EPILEPSY; HUMAN; INTELLECTUAL IMPAIRMENT; IRRITABILITY; LENNOX GASTAUT SYNDROME; NAUSEA AND VOMITING; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; REVIEW; SEIZURE; SIDE EFFECT; WEIGHT GAIN;

EID: 33845716621     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.67.12_suppl_4.s52     Document Type: Review

References (27)

1. Sunder TR. Meeting the challenge of epilepsy in persons with multiple handicaps. J Child Neurol 1997;12(suppl 1):S38-S43.
2. Coulter DL. Comprehensive management of epilepsy in persons with mental retardation. Epilepsia 1997:38(suppl 4):S24-S31.
3. Pellock JM, Morton LD. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil Res Rev 2000;6:309-326.
4. American Association on Mental Retardation. Mental retardation: definition, classification and systems of support. 10th ed. Annapolis Junction, MD: AAMR Publications, 2002.
5. Steffenburg U, Hagberg G, Kyllerman M. Characteristics of seizures in a population-based series of mentally retarded children with active epilepsy. Epilepsia 1996:37:850-856.
6. Ashwal S, Russman BS, Blasco PA, et al. Practice parameter: diagnostic assessment of the child with cerebral palsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the Practice Committee of the Child Neurology Society. Neurology 2004;62:851-863.
7. Desai P, Talwar D. Nonepileptic events in normal and neurologically handicapped children: a video-EEG study. Pediatr Neurol 1992;8:127-129.
8. Paul A. Epilepsy or stereotypy? Diagnostic issues in learning disabilities. Seizure.1997;6:111-120.
9. Holmes GI, McKeever M, Russman BS. Abnormal behavior or epilepsy? Use of long-term EEG and video monitoring with severely to profoundly mentally retarded patients with seizures. Am J Ment Defic 1983;87:456-458.
10. De Los Reyes EC, Sharp GB, Williams JP, Hale SE. Levetiracetam in the treatment of Lennox-Gastaut syndrome. Pediatr Neurol 2004;30:254-256.
11. Devinsky O. What do you do when they grow up? Approaches to seizures in developmentally delayed adults. Epilepsia 2002;43(suppl 3):71-79.
12. Felbamate Study Group in the Lennox-Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy. (Lennox-Gastaut) N Eng J Med 1993;328:29-33.
13. French JA, Gidal BE. Antiepileptic drug interactions. Epilepsia 2000;41(suppl 8):530-536.
14. Jancar J, Jancar MP. Age-related fractures in people with intellectual disability and epilepsy. J Intellect Disabil Res 1998;42:429-433.
15. Epsie CA, Paul A, Graham M, et al. The Epilepsy Outcome Scale: the development of a measure for use with carers of people with epilepsy plus intellectual disability. J Intellect Disabil Res 1998;42:90-96.
16. Sabaz M, Cairns DR, Lawson JA, et al. The health-related quality of life of children with refractory epilepsy: a comparison of those with and without intellectual disability. Epilepsia 2001;42:621-628.
17. Schmidt D. Reduction of two-drug therapy in intractable epilepsy. Epilepsia 1983;24:368-376.
18. Schmidt D. Single drug therapy for intractable epilepsy. J Neurol 1983;229:221-226.
19. Bennett HS, Dunlop T, Ziring P. Reduction of polypharmacy for epilepsy in an institution for the retarded. Dev Med Child Neurol 1983;25:735-737.
20. Clancy RR, Blubaugh KM, Pippidis M, et al. Antiepileptic drug monotherapy and behavioral disorders in institutionalized mentally retarded children with epilepsy. Ann Neurol 1991;30:493.
21. Poindexter AR, Berglund JA, Kolstoe PD. Changes in antiepileptic drug prescribing patterns in large institutions: preliminary results of a five-year experience. Ann J Ment Retard 1993;98:34-40.
22. Mirza WU, Credeur LJ, Penry JK. Results of antiepileptic drug reduction in patients with multiple handicaps and epilepsy. Drug Invest 1993;5:320-326.
23. Pellock JM, Morton LD. Treatment of epilepsy in the multiply handicapped. Ment Retard Dev Disabil Res Rev 2000:6:309-323.
24. Marcus JC. Stopping antiepileptic therapy in mentally-retarded, epileptic children. Neuropediatrics 1998;29:26-28.
25. Delgado MR, Riela MR, Mills J, et al. Discontinuation of antiepileptic drug treatment after two seizure-free years in children with cerebral palsy. Pediatrics 1996;97:192-197.
26. Nordli DR, DeVivo DC. The ketogenic diet revisited: back to the future. Epilepsia 1997;38:743-749.
27. Sherrard J, Tonge BJ, Ozanne-Smith J. Injury risk in young people with intellectual disability. J Intellect Disabil Res 2002;46:6-16.